<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511431728</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511431728</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Jarius</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511431728">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Paul</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511431728">2</xref>
<xref ref-type="aff" rid="aff3-1352458511431728">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Franciotta</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff4-1352458511431728">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>de Seze</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff5-1352458511431728">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Münch</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff6-1352458511431728">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Salvetti</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff7-1352458511431728">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ruprecht</surname><given-names>K</given-names></name>
<xref ref-type="aff" rid="aff6-1352458511431728">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liebetrau</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff8-1352458511431728">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wandinger</surname><given-names>KP</given-names></name>
<xref ref-type="aff" rid="aff9-1352458511431728">9</xref>
<xref ref-type="aff" rid="aff10-1352458511431728">10</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Akman-Demir</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff11-1352458511431728">11</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Melms</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff12-1352458511431728">12</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kristoferitsch</surname><given-names>W</given-names></name>
<xref ref-type="aff" rid="aff13-1352458511431728">13</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wildemann</surname><given-names>B</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511431728">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511431728"><label>1</label>Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany</aff>
<aff id="aff2-1352458511431728"><label>2</label>NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité University Medicine Berlin, and Max Delbrück Center for Molecular Medicine, Berlin, Germany</aff>
<aff id="aff3-1352458511431728"><label>3</label>Clinical and Experimental Multiple Sclerosis Research Center – Charité University Medicine Berlin, Berlin, Germany</aff>
<aff id="aff4-1352458511431728"><label>4</label>IRCCS, National Neurological Institute C. Mondino, Pavia, Italy</aff>
<aff id="aff5-1352458511431728"><label>5</label>Clinique Neurologique, CHU de Strasbourg, Strasbourg, France</aff>
<aff id="aff6-1352458511431728"><label>6</label>Department of Neurology, Charité University Medicine Berlin, Berlin, Germany</aff>
<aff id="aff7-1352458511431728"><label>7</label>Centre for Experimental Neurological Therapies, Sapienza University, Rome, Italy</aff>
<aff id="aff8-1352458511431728"><label>8</label>Department of Neurology, Dr.-Horst-Schmidt-Klinik, Wiesbaden, Germany</aff>
<aff id="aff9-1352458511431728"><label>9</label>Institute for Neuroimmunology and Clinical MS Research, University Medical Center Eppendorf, Hamburg, Germany</aff>
<aff id="aff10-1352458511431728"><label>10</label>Institute for Experimental Immunology, affiliated to Euroimmun, Lübeck, Germany</aff>
<aff id="aff11-1352458511431728"><label>11</label>Department of Neurology, University of Istanbul, Istanbul, Turkey</aff>
<aff id="aff12-1352458511431728"><label>12</label>Department of Neurology, University of Tuebingen, Tuebingen, Germany</aff>
<aff id="aff13-1352458511431728"><label>13</label>Department of Neurology, Sozialmedizinisches Zentrum Ost – Donauspital, Vienna, Austria</aff>
<author-notes>
<corresp id="corresp1-1352458511431728">B Wildemann, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany. Email: <email>brigitte.wildemann@med.uni-heidelberg.de</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>8</issue>
<fpage>1135</fpage>
<lpage>1143</lpage>
<history>
<date date-type="received">
<day>18</day>
<month>8</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>18</day>
<month>10</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>11</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1352458511431728">
<title>Background:</title>
<p>Neuromyelitis optica (NMO, Devic syndrome) and myasthenia gravis (MG) are rare antibody-mediated autoimmune disorders. Concurrent incidence has been reported in only few patients, mostly non-Caucasians.</p>
</sec>
<sec id="section2-1352458511431728">
<title>Objective:</title>
<p>To report on ten Caucasian patients with NMO spectrum disorders (NMOSD) and MG and to provide a comprehensive review of the literature.</p>
</sec>
<sec id="section3-1352458511431728">
<title>Method:</title>
<p>Retrospective study.</p>
</sec>
<sec id="section4-1352458511431728">
<title>Results:</title>
<p>In total, 26 patients (m:f = 1:12; Caucasian in 12) with MG (generalized in 17) and NMOSD (NMO in 21, longitudinally extensive transverse myelitis in five) were identified from the authors’ own files (<italic>n</italic> = 10) and the previous literature (<italic>n</italic> = 16). MG preceded NMOSD in 24/25 cases (96%). AQP4-Ab were tested in 20 patients and were positive in 17 (85%). Twenty out of 25 patients (80%) had been treated with thymectomy or thymic irradiation, which preceded NMOSD in all cases (median latency, 12 years; range, 0.3–32). At last follow-up, complete remission of MG was reported in 15/22 (68%), and MG was well controlled with pyridostigmine in three. Co-existing autoimmune disorders or autoimmune antibodies were reported in 17 patients.</p>
</sec>
<sec id="section5-1352458511431728">
<title>Conclusion:</title>
<p>Our study demonstrates that i) AQP4-Ab-positive NMOSD are more commonly associated with MG in Caucasians than previously thought; ii) MG precedes NMOSD in most cases, often by more than a decade; iii) NMOSD almost exclusively occur in females with juvenile or early-onset MG; and iv) MG frequently takes an unusually mild course in patients with NMOSD. A history of thymectomy could be a possible risk factor for the later development of NMOSD. We recommend testing for AQP4-Ab in MG patients presenting with atypical motor or optic symptoms.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Acetylcholine receptor antibody (AchR-Ab)</kwd>
<kwd>aquaporin-4 antibody (AQP4-Ab)</kwd>
<kwd>longitudinally extensive transverse myelitis</kwd>
<kwd>myasthenia gravis</kwd>
<kwd>neuromyelitis optica (Devic disease)</kwd>
<kwd>NMO-IgG</kwd>
<kwd>optic neuritis</kwd>
<kwd>thymectomy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section6-1352458511431728" sec-type="intro">
<title>Introduction</title>
<p>Neuromyelitis optica (NMO) is a rare inflammatory disorder of the central nervous system (CNS), predominantly affecting the spinal cord and optic nerves.<sup><xref ref-type="bibr" rid="bibr1-1352458511431728">1</xref><xref ref-type="bibr" rid="bibr2-1352458511431728"/><xref ref-type="bibr" rid="bibr3-1352458511431728"/><xref ref-type="bibr" rid="bibr4-1352458511431728"/>-<xref ref-type="bibr" rid="bibr5-1352458511431728">5</xref></sup> In 60–80% of cases, NMO is associated with antibodies to aquaporin-4, the most abundant water channel in the CNS (termed NMO- IgG, or AQP4-Ab).<sup><xref ref-type="bibr" rid="bibr6-1352458511431728">6</xref><xref ref-type="bibr" rid="bibr7-1352458511431728"/><xref ref-type="bibr" rid="bibr8-1352458511431728"/>-<xref ref-type="bibr" rid="bibr9-1352458511431728">9</xref></sup> Recent data from immunological and histopathological studies and passive transfer experiments suggest that these autoantibodies are pathogenic.<sup><xref ref-type="bibr" rid="bibr3-1352458511431728">3</xref>,<xref ref-type="bibr" rid="bibr4-1352458511431728">4</xref>,<xref ref-type="bibr" rid="bibr10-1352458511431728">10</xref><xref ref-type="bibr" rid="bibr11-1352458511431728"/><xref ref-type="bibr" rid="bibr12-1352458511431728"/>-<xref ref-type="bibr" rid="bibr13-1352458511431728">13</xref></sup></p>
<p>NMO is frequently associated with other autoimmune disorders (e.g. systemic lupus erythematosus, Sjögren syndrome, or coeliac disease) or with corresponding serum autoantibodies such as ANA, dsDNA, SS-A, or SS-B.<sup><xref ref-type="bibr" rid="bibr14-1352458511431728">14</xref><xref ref-type="bibr" rid="bibr15-1352458511431728"/>-<xref ref-type="bibr" rid="bibr16-1352458511431728">16</xref></sup> However, coexistence of NMO and myasthenia gravis (MG) has only rarely been reported, especially in Caucasian patients. Here we report the occurrence of AQP4-Ab-positive NMO or its limited form, AQP4-Ab-positive longitudinally extensive transverse myelitis (LETM)<sup><xref ref-type="bibr" rid="bibr17-1352458511431728">17</xref>,<xref ref-type="bibr" rid="bibr18-1352458511431728">18</xref></sup> in 10 Caucasian patients with acetylcholine receptor antibody (AchR-Ab)-positive MG. Of these, eight had been treated by thymectomy or thymic irradiation prior to onset of NMO spectrum disorder (NMOSD). In addition, we provide a comprehensive review of the existing English language literature.</p>
</sec>
<sec id="section7-1352458511431728" sec-type="methods">
<title>Patients and methods</title>
<p>The diagnosis of NMO was made according to the 2006 revised diagnostic criteria.<sup><xref ref-type="bibr" rid="bibr19-1352458511431728">19</xref></sup> LETM was defined as clinically defined transverse myelitis with lesions extending over three or more vertebral segments as determined by magnetic resonance imaging (MRI). All cases of NMOSD and MG treated by the authors were included. Patients were seen between 2006 and 2011. Further cases were identified by searches of PubMed for articles published from January 1966 to June 2011 using the term “(neuromyelitis OR Devic OR myelitis OR optic neuritis) AND myasthenia”. The Mann–Whitney <italic>U</italic> test was used to test for significant differences between continuous variables and Fisher’s exact test (two-tailed) to compare proportions.</p>
</sec>
<sec id="section8-1352458511431728" sec-type="results">
<title>Results</title>
<p>A total of 26 patients with NMOSDs were identified, 10 from the authors’ own files and 16 from the existing English language literature. A short summary of all patients’ demographic, clinical, and serological findings as well as references for the cases detailed in the literature are given in <xref ref-type="table" rid="table1-1352458511431728">Table 1</xref> and <xref ref-type="table" rid="table2-1352458511431728">Table 2</xref> Six demonstrative case reports can be found in the online supplement (supplement A); the patients gave written informed consent prior to publication.</p>
<table-wrap id="table1-1352458511431728" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical and paraclinical findings in 10 Caucasian patients with MG and AQP4-Ab positive NMO/LETM.</p>
</caption>
<graphic alternate-form-of="table1-1352458511431728" xlink:href="10.1177_1352458511431728-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">No</th>
<th align="left">Sex, Origin</th>
<th align="left">Age at onset of MG</th>
<th align="left">Age at thym-ectomy</th>
<th align="left">Histology of thymus</th>
<th align="left">Age at onset of NMO/ LETM</th>
<th align="left">ON relapses</th>
<th align="left">Myelitis relapses</th>
<th align="left">Spinal MRI<sup><xref ref-type="table-fn" rid="table-fn1-1352458511431728">†</xref></sup></th>
<th align="left">Brain MRI lesions</th>
<th align="left">AchR- Ab, serum (nnmol/l)</th>
<th align="left">AQP4-Ab, serum</th>
<th align="left">WBC/µl <sup><xref ref-type="table-fn" rid="table-fn1-1352458511431728">‡</xref></sup>, CSF</th>
<th align="left">OCBs, CSF/ serum</th>
<th align="left">Other autoantibodies/ autoimmune disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F, Cauc</td>
<td>31</td>
<td>36</td>
<td>Hyperplasia</td>
<td>59, M</td>
<td>0, VEP delayed</td>
<td>2</td>
<td>7</td>
<td>MO</td>
<td>Pos (6.8)</td>
<td>Pos (CBA)</td>
<td>60</td>
<td>Pos/neg</td>
<td>ANA 1:640, TPO-Ab</td>
</tr>
<tr>
<td>2</td>
<td>F, Cauc</td>
<td>26</td>
<td>Not done</td>
<td>Not done</td>
<td>26, ON</td>
<td>Several</td>
<td>2</td>
<td>6</td>
<td>Non- specific WML</td>
<td>Pos (26.3)</td>
<td>Pos (CBA and FIPA, 139 FU)</td>
<td>209</td>
<td>Neg/neg,pos/ pos</td>
<td>Weakly positive ANA</td>
</tr>
<tr>
<td>3</td>
<td>F, Cauc</td>
<td>23</td>
<td>23</td>
<td>Hyperplasia</td>
<td>43, M</td>
<td>0, VEP normal</td>
<td>3</td>
<td>7</td>
<td>No</td>
<td>Pos (29)</td>
<td>Pos (CBA)</td>
<td>&lt;5</td>
<td>Neg/neg</td>
<td>Celiac disease, ovary dysfunction, ANA, dsDNA-Ab</td>
</tr>
<tr>
<td>4</td>
<td>F, Cauc</td>
<td>22</td>
<td>Not done</td>
<td>Not done</td>
<td>20, ON</td>
<td>6</td>
<td>5</td>
<td>5</td>
<td>No</td>
<td>Pos (&gt;100)</td>
<td>Pos (CBA and FIPA, 711 FU)</td>
<td>52</td>
<td>Pos/neg</td>
<td>Hashimoto encephalitis; TPO-Ab, TG-Ab</td>
</tr>
<tr>
<td>5</td>
<td>F, Cauc</td>
<td>25</td>
<td>Not done<xref ref-type="table-fn" rid="table-fn1-1352458511431728">*</xref></td>
<td>Not done<xref ref-type="table-fn" rid="table-fn1-1352458511431728">*</xref></td>
<td>66, M</td>
<td>0, VEP delayed</td>
<td>2</td>
<td>3</td>
<td>‘Vasculo-pathic’ lesions</td>
<td><xref ref-type="table-fn" rid="table-fn1-1352458511431728">***</xref></td>
<td>Pos (CBA)</td>
<td>Normal</td>
<td>Neg/neg</td>
<td>Weakly positive ANA, type 1 diabetes mellitus</td>
</tr>
<tr>
<td>6</td>
<td>F, Cauc</td>
<td>21</td>
<td>35</td>
<td>Hyperplasia</td>
<td>67, M</td>
<td>0, VEP normal<xref ref-type="table-fn" rid="table-fn1-1352458511431728">**</xref></td>
<td>2</td>
<td>4</td>
<td>No</td>
<td>Pos (12.5)</td>
<td>Pos (CBA 1:1280)</td>
<td>0</td>
<td>Neg/neg</td>
<td>Positive GAD-Ab, late onset type I diabetes mellitus.</td>
</tr>
<tr>
<td>7</td>
<td>F, Cauc</td>
<td>33</td>
<td>35</td>
<td>Normal</td>
<td>47, M</td>
<td>3</td>
<td>2</td>
<td>5</td>
<td>No</td>
<td>Pos</td>
<td>Pos (CBA)</td>
<td>15</td>
<td>Neg/neg</td>
<td>SS</td>
</tr>
<tr>
<td>8</td>
<td>F, Cauc</td>
<td>13</td>
<td>14</td>
<td>Normal</td>
<td>28, ON</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>MO</td>
<td>Pos</td>
<td>Pos (IHC, CBA)</td>
<td>8</td>
<td>Neg/neg; Pos/ neg</td>
<td>None</td>
</tr>
<tr>
<td>9</td>
<td>F, Cauc</td>
<td>11</td>
<td>13</td>
<td>Lymphocytic thymitis</td>
<td>32, ON</td>
<td>1</td>
<td>1</td>
<td>12</td>
<td>No</td>
<td>Pos (63.4)</td>
<td>Pos (CBA)</td>
<td>2</td>
<td>Neg/neg</td>
<td>SLE</td>
</tr>
<tr>
<td>10</td>
<td>F, Cauc</td>
<td>29</td>
<td>Not done</td>
<td>Not done</td>
<td>55, ON</td>
<td>1</td>
<td>2</td>
<td>6</td>
<td>No</td>
<td>Pos (7.6)</td>
<td>Pos (CBA)</td>
<td>2</td>
<td>Pos/neg</td>
<td>None</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458511431728">
<p>AchR-Ab, acetylcholine receptor antibodies; AQP4-Ab, aquaporin-4 antibodies; ANA, anti-nuclear antibodies; CBA, cell-based assay; CSF, cerebrospinal fluid; dsDNA-Ab, double-stranded DNA antibodies; IHC, immunohistochemistry; FIPA, fluorescence immunoprecipitation assays; FU, fluorescence units (peak values); M, myelitis; MO, medulla oblongata; OCB, CSF-restricted oligoclonal bands; ON, optic neuritis; SLE, systemic lupus erythematosus; SS, Sjögren syndrome; TG-Ab, thyroglobulin antibodies; TPO-Ab, thyroid peroxidase antibodies; WBC, white blood cells; WML, white matter lesions. Neg, negative; pos, positive; <sup>†</sup> Vertebral segments, maximum extension; <sup>‡</sup> peak values; * Radiation of the thymus shortly after onset of MG. ** Borderline P100 latency in both eyes. *** Test not available in 1956 when the diagnosis of MG was established; negative in a sample taken in 2010.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1352458511431728" position="float">
<label>Table 2.</label>
<caption>
<p>Epidemiological, radiological and serological findings from 16 MG patients with NMO (1-15) or isolated LETM (16) published in the English language literature.</p>
</caption>
<graphic alternate-form-of="table2-1352458511431728" xlink:href="10.1177_1352458511431728-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Ref</th>
<th align="left">Sex, Origin</th>
<th align="left">Age at onset of MG</th>
<th align="left">Age at thymect-omy</th>
<th align="left">Histology of thymus</th>
<th align="left">Age at onset of NMO/LETM</th>
<th align="left">No. of ON attacks</th>
<th align="left">No of. myelitis attacks</th>
<th align="left">Spinal MRI<sup><xref ref-type="table-fn" rid="table-fn2-1352458511431728">†</xref></sup></th>
<th align="left">Brain MRI lesions</th>
<th align="left">AchR-Ab, serum (nnmol/l)</th>
<th align="left">AQP4-Ab, serum</th>
<th align="left">WBC/µl<sup><xref ref-type="table-fn" rid="table-fn2-1352458511431728">‡</xref></sup>, CSF</th>
<th align="left">OCBs, CSF/ serum</th>
<th align="left">Other autoantibodies/ auto- immune disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>[20]</italic></td>
<td>M, NA</td>
<td>49</td>
<td>49</td>
<td>Thymoma</td>
<td>49, ON/M</td>
<td>1</td>
<td>1</td>
<td>18</td>
<td>No</td>
<td>Pos</td>
<td>Not done</td>
<td>289</td>
<td>NA</td>
<td>None stated</td>
</tr>
<tr>
<td><italic>[21]</italic></td>
<td>F, NA</td>
<td>27</td>
<td>28</td>
<td>NA</td>
<td>32, M</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>No</td>
<td>NA</td>
<td>Not done</td>
<td>NA</td>
<td>Neg/neg</td>
<td>ANA 1:320</td>
</tr>
<tr>
<td><italic>[22]</italic></td>
<td>F, Asian</td>
<td>23</td>
<td>NA</td>
<td>Hyperplasia</td>
<td>48, ON</td>
<td>1</td>
<td>1</td>
<td>8</td>
<td>No</td>
<td>Pos (1304)</td>
<td>Neg (IHC)</td>
<td>17</td>
<td>Neg/neg</td>
<td>Thyroiditis, TG+ TPO-Ab; ANA</td>
</tr>
<tr>
<td><italic>[22]</italic></td>
<td>F, Asian</td>
<td>NA<xref ref-type="table-fn" rid="table-fn2-1352458511431728">*</xref></td>
<td>Not done</td>
<td>Not done</td>
<td>63, ON</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>No</td>
<td>Pos (141)</td>
<td>Neg (IHC)</td>
<td>0</td>
<td>Neg/neg</td>
<td>SLE, Grave’s disease</td>
</tr>
<tr>
<td><italic>[23]</italic></td>
<td>M, Asian</td>
<td>29</td>
<td>30</td>
<td>Hyperplasia</td>
<td>45, M</td>
<td>2</td>
<td>2</td>
<td>5</td>
<td>No</td>
<td>Pos</td>
<td>Not done</td>
<td>NA</td>
<td>NA</td>
<td>ANA</td>
</tr>
<tr>
<td><italic>[24]</italic></td>
<td>F, Asian</td>
<td>28</td>
<td>NA</td>
<td>Hyperplasia</td>
<td>36, ON</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
<td>NA</td>
<td>Pos</td>
<td>Not done</td>
<td>NA</td>
<td>NA</td>
<td>None stated</td>
</tr>
<tr>
<td><italic>[25]</italic></td>
<td>F, Asian</td>
<td>28</td>
<td>30</td>
<td>NA</td>
<td>38, ON</td>
<td>7</td>
<td>2</td>
<td>&gt;3</td>
<td>Yes</td>
<td>Pos</td>
<td>Pos (IHC)</td>
<td>32</td>
<td>Pos/neg</td>
<td>None stated</td>
</tr>
<tr>
<td><italic>[26]</italic></td>
<td>F, Asian</td>
<td>44</td>
<td>Not done</td>
<td>Not done</td>
<td>49, M</td>
<td>4</td>
<td>3</td>
<td>&gt;3</td>
<td>Multifocal</td>
<td>Pos (4.5)</td>
<td>Pos (IHC)</td>
<td>Normal</td>
<td>Neg/neg</td>
<td>None stated</td>
</tr>
<tr>
<td><italic>[27]</italic></td>
<td>F, Asian</td>
<td>18</td>
<td>20</td>
<td>NA</td>
<td>29, ON</td>
<td>2</td>
<td>6</td>
<td>4</td>
<td>No</td>
<td>Pos</td>
<td>Pos (ELISA)</td>
<td>NA</td>
<td>NA</td>
<td>None stated</td>
</tr>
<tr>
<td><italic>[27]</italic></td>
<td>F, Asian</td>
<td>20</td>
<td>28</td>
<td>Hyperplasia</td>
<td>41, ON</td>
<td>7</td>
<td>4</td>
<td>7</td>
<td>No</td>
<td>Pos (40)</td>
<td>Pos (ELISA)</td>
<td>NA</td>
<td>NA</td>
<td>None stated</td>
</tr>
<tr>
<td><italic>[28]</italic></td>
<td>F, Asian</td>
<td>27</td>
<td>28</td>
<td>Normal(?)</td>
<td>38, ON/M</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>No</td>
<td>Pos</td>
<td>Not done</td>
<td>NA</td>
<td>NA</td>
<td>None stated</td>
</tr>
<tr>
<td><italic>[28]</italic></td>
<td>F, African</td>
<td>38</td>
<td>38</td>
<td>Hyperplasia</td>
<td>39, ON</td>
<td>6</td>
<td>3</td>
<td>7</td>
<td>Few</td>
<td>Pos</td>
<td>Pos (IHC)</td>
<td>10</td>
<td>Neg/neg</td>
<td>Asthma; family history of ‘MS’</td>
</tr>
<tr>
<td><italic>[28]</italic></td>
<td>F, African</td>
<td>36</td>
<td>37</td>
<td>Hyperplasia</td>
<td>42, ON</td>
<td>1</td>
<td>2</td>
<td>10</td>
<td>No</td>
<td>Pos</td>
<td>Pos (IHC)</td>
<td>2</td>
<td>Neg/neg</td>
<td>Asthma; GAD-Ab positive SPS(?), low titre ANA</td>
</tr>
<tr>
<td><italic>[28]</italic><sup><xref ref-type="table-fn" rid="table-fn2-1352458511431728">§</xref></sup></td>
<td>F, Cauc</td>
<td>17</td>
<td>17</td>
<td>Hyperplasia</td>
<td>19, ON</td>
<td>6</td>
<td>10</td>
<td>5</td>
<td>No</td>
<td>Pos (72)</td>
<td>Neg (IHC, CBA, FIPA)</td>
<td>55</td>
<td>Pos/neg</td>
<td>ANA 1:1024, anti-cardiolipin antibodies</td>
</tr>
<tr>
<td><italic>[29]</italic></td>
<td>F, NA</td>
<td>10</td>
<td>12</td>
<td>NA</td>
<td>26, M</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>No</td>
<td>Pos</td>
<td>Pos (IHC)</td>
<td>Elevated</td>
<td>NA</td>
<td>ANA, “no SLE”</td>
</tr>
<tr>
<td><italic>[30]</italic></td>
<td>F, Cauc</td>
<td>NA<sup><xref ref-type="table-fn" rid="table-fn2-1352458511431728">#</xref></sup></td>
<td>NA</td>
<td>NA</td>
<td>41, ON</td>
<td>1</td>
<td>2</td>
<td>16</td>
<td>No</td>
<td>Pos</td>
<td>Not done</td>
<td>NA</td>
<td>Neg/neg</td>
<td>SLE; ANA, dsDNA-Ab, ASMA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1352458511431728">
<p>AchR-Ab: acetylcholine receptor antibodies; AQP4-Ab, aquaporin-4 antibodies; ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemistry; SLE, systemic lupus erythematosus; SPS, stiff person syndrome; M, male; F, female; NA, not available. * AchR-Ab already positive at NMO onset. <sup>†</sup> Vertebral segments, maximum extension; <sup>‡</sup> peak values; <sup>§</sup> data updated (DF). <sup>#</sup> Age not specified, but onset of MG preceded onset of NMO.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section9-1352458511431728">
<title>Demographic data</title>
<p>Twenty-four out of 26 (92%) patients in the total cohort were females, corresponding to a sex ratio (m:f) of 1:13. Twelve patients were of Caucasian origin, nine of Asian, and two of African descent; in three previously published cases, no data on ethnic background were provided.</p>
</sec>
<sec id="section10-1352458511431728">
<title>Clinical data</title>
<p>The median age at onset of MG was 26.5 years (range, 10–49). At the age of MG onset, 5/24 patients (21%) were &lt;= 18 years old; including these patients, 18/24 patients (75%) were &lt; 30 years at MG onset; in two cases the age at onset of MG was not stated by the authors. MG was ocular in six and generalized in 17 patients; in three cases the clinical subtype was not reported by the authors. MG preceded NMOSD in 24/25 cases, while one patient developed generalized MG during steroid treatment for a (third) attack of optic neuritis (ON); in one case, the authors did not report whether MG preceded NMOSD or not. Median age at onset of NMOSD was 41 (range, 19–67). Median latency between onset of MG and onset of NMOSD was 15 years (range, 0.6–46). The number of LETM attacks at last follow-up ranged between 1–10 (median 2; <italic>n</italic> = 25). In total, 21 patients had also experienced episodes of ON (median 2; range 1–7) and met the revised diagnostic criteria for NMO,<sup><xref ref-type="bibr" rid="bibr19-1352458511431728">19</xref></sup> and two further patients had no clinical history of ON but did have delayed visual evoked potential. The presenting manifestation of NMOSD was isolated ON in 16/26 patients (61%). Eight presented initially with myelitis (31%) and only two with simultaneous myelitis and ON.</p>
</sec>
<sec id="section11-1352458511431728">
<title>Brain and spinal cord MRI findings</title>
<p>White matter brain lesions were seen in five patients and brain stem involvement in two; no brain lesions were found in 18; no data were available for one patient. Spinal cord lesions spanned over 3–18 segments (peak values; median 6; <italic>n</italic> = 23). See <xref ref-type="fig" rid="fig1-1352458511431728">Figure 1</xref> for typical MRI findings.</p>
<fig id="fig1-1352458511431728" position="float">
<label>Figure 1.</label>
<caption>
<p>Exemplary magnetic resonance imaging (MRI) findings. (A) MRI of the cervical spine of a 45-year-old woman (case 3; <xref ref-type="table" rid="table1-1352458511431728">Table 1</xref> and Online supplement A) with myasthenia gravis (MG) and AQP4-Ab-positive longitudinal extensive transverse myelitis (T2; upper inset: DWI, coronal; lower inset: T2, coronal). (B) Coronal MRI of the brain of a 32-year-old woman (case 9; <xref ref-type="table" rid="table1-1352458511431728">Table 1</xref> and online supplement A) with MG and AQP4-Ab positive severe unilateral optic neuritis (T1 with Gd) showing marked swelling and contrast enhancement of the right optic nerve.</p>
</caption>
<graphic xlink:href="10.1177_1352458511431728-fig1.tif"/>
</fig>
</sec>
<sec id="section12-1352458511431728">
<title>Cerebrospinal fluid findings</title>
<p>Cerebrospinal fluid (CSF) results were available for 21/26 patients. CSF-restricted oligoclonal bands (OCBs) were present in six patients (29%); no OCBs were detected in 12 cases (57%); one patient had no OCBs at first tap and identical OCBs in serum and CSF, indicating systemic IgG synthesis, at follow-up. CSF pleocytosis was reported in 12 patients (peak values, 8–289 cells/µl), while seven had a normal cell count.</p>
</sec>
<sec id="section13-1352458511431728">
<title>AQP4-Ab serostatus</title>
<p>AQP4-Ab were tested in 20/26 patients and were positive in 17 (85%). One patient was consistently negative for AQP4-Ab in several independent recombinant assays, while three AQP4-Ab negative patients reported in the literature had been tested only by immunohistochemistry, a method with comparatively low sensitivity.<sup><xref ref-type="bibr" rid="bibr31-1352458511431728">31</xref><xref ref-type="bibr" rid="bibr32-1352458511431728"/>-<xref ref-type="bibr" rid="bibr33-1352458511431728">33</xref></sup></p>
</sec>
<sec id="section14-1352458511431728">
<title>AchR-Ab serostatus</title>
<p>AchR-Ab were positive in 24 of the 25 cases with available data. In one case with complete recovery from MG, AchR-Ab turned negative later in the disease course. In one further case, AchR-Ab was negative when MG was stable, but no previous results were available retrospectively. AchR levels were reported in 11 cases and ranged between 4.5–1304 nmol/l (median 34.5).</p>
</sec>
<sec id="section15-1352458511431728">
<title>Thymic pathology</title>
<p>Thymectomy was performed in 19/25 patients (76%) and preceded NMOSD in all of them, with a median latency between the two events of 12 years (range 0.3–32). In one patient, irradiation of the thymus instead of thymectomy was carried out. In one additional case, the authors did not mention whether thymectomy was performed. Histology revealed thymic hyperplasia in 10 patients, thymitis in one, thymoma in one, and was normal in two; in five cases the histological results were not reported by the authors.</p>
</sec>
<sec id="section16-1352458511431728">
<title>MG outcome</title>
<p>At last follow-up, complete remission of MG was reported in 15/22 (68%) (although the antibody remained detectable in some), and MG was well controlled with pyridostigmine in three patients.</p>
</sec>
<sec id="section17-1352458511431728">
<title>NMO outcome</title>
<p>Data were available from 21/26 patients (10 from the authors’ series, 11 from the previous literature). In 13/21 (62%) patients, significant visual impairment or paresis was present at last follow-up (authors’ series: 1 × wheel-chair bound, 3 × unilateral or bilateral blindness, 1 × severe visual loss and severe monoparesis, 1 × hemiparesis and incontinence; previous cases: 1 × bilateral blindness and tetraplegia, 1 × wheel chair bound, 4 × paraparesis and (functionally or completely) blind (3) or severe visual loss (1), 1 × moderate paraparesis, 1 × bilateral visual loss, sensorimotor tetraplegia, bladder dysfunction during relapse and ‘persisting severe disabilities’ at last follow-up). In contrast, only mild disability and/or only sensory symptoms were noted at last follow-up in eight patients. However, both the median disease duration (1.5 vs. 9 years) and the median number of attacks (2 vs. 4) was lower in patients with beneficial outcome, and 3/8 patients with no significant disability at last follow-up had experienced only LETM but no ON attacks. Of the five patients for whom the outcome was not reported, one had developed paraplegia and bilateral functional blindness during the last documented relapse and paraparesis and brain stem encephalitis during previous relapses; another had experienced a relapse of simultaneous ON and myelitis with paresis and bladder dysfunction and later an attack of bilateral ON and brain stem encephalitis; and one patient had experienced tetraparesis and severe visual loss during some of the attacks. In several cases, relapses occurred despite immunosuppressive treatment, while in some immunosuppression resulted in long-term clinical stabilization over several years; see the supplementary table (online supplement B) for details.</p>
</sec>
<sec id="section18-1352458511431728">
<title>Co-existing autoimmunity</title>
<p>Co-existing autoimmune disorders or autoimmune antibodies other than AchR-Ab and AQP4-Ab were reported in 17 patients (see <xref ref-type="table" rid="table1-1352458511431728">Table 1</xref> and <xref ref-type="table" rid="table2-1352458511431728">Table 2</xref> for details).</p>
</sec>
<sec id="section19-1352458511431728">
<title>Comparison between Caucasian and non-Caucasian patients</title>
<p>No statistically significant differences between Caucasian and non-Caucasian patients were found with regard to the median age at MG onset (23 vs. 28 years), the median age at NMOSD onset (45 vs. 41 years), the median spinal cord lesion length (5.5 vs. 6), or the frequency of brain lesions (33.3% vs. 30%). The two groups also did not differ significantly with regard to sex ratio, number of ON events, or number of myelitis events. The median latency between onset of MG and onset of NMOSD as well as the median latency between thymectomy and onset of NMOSD was longer in the non-Caucasian group (23.5 years vs. 11 and 19 vs. 9 years, respectively; <italic>p</italic> &lt; 0.03 and <italic>p</italic> &lt; 0.02, respectively; Mann–Whitney <italic>U</italic> test, two-tailed); however, when <italic>p</italic>-values were corrected for multiple comparison according to Bonferroni the difference was not significant. More patients were positive for AQP4-Ab in the authors’ series than among the previously published non-Caucasian cases (100% vs. 75%); however, the difference was not statistically significant, and all AQP4-Ab negatives were only tested by indirect immunofluorescence on murine brain section, a method that has been repeatedly shown to be insufficiently sensitive compared to assays employing recombinant human AQP4 as used for the Caucasian patients.<sup><xref ref-type="bibr" rid="bibr31-1352458511431728">31</xref><xref ref-type="bibr" rid="bibr32-1352458511431728"/>-<xref ref-type="bibr" rid="bibr33-1352458511431728">33</xref></sup></p>
</sec>
</sec>
<sec id="section20-1352458511431728" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we report on the largest series of patients with NMOSD and co-existing MG and provide a review of all so far published cases. It is well known that patients with one autoimmune disease have an increased risk of developing further autoimmune diseases. In fact, clinical and serological findings of co-existing autoimmunity are present in as many as 30–75% of patients with NMO.<sup><xref ref-type="bibr" rid="bibr1-1352458511431728">1</xref>,<xref ref-type="bibr" rid="bibr5-1352458511431728">5</xref>,<xref ref-type="bibr" rid="bibr19-1352458511431728">19</xref>,<xref ref-type="bibr" rid="bibr30-1352458511431728">30</xref></sup> However, only very few patients with NMOSD and acetylcholine receptor-positive MG have been described in the previous English language literature (see <xref ref-type="table" rid="table2-1352458511431728">Table 2</xref> for references). Moreover, most previously reported patients were of Asian or African descent, and AQP4-Ab had not been determined or was negative in more than half of them, while all 10 patients reported here are of Caucasian descent and are positive for serum AQP4-Ab.</p>
<p>Visual and motor symptoms caused by MG are usually easily distinguishable from those caused by ON and myelitis, respectively, on clinical grounds. However, mild myelitis or ON attacks are not rare in patients with NMO. Newly occurring atypical visual disturbances, weakness, or respiratory insufficiency in patients with MG should therefore prompt physicians to consider also co-existing NMO and to test for AQP4-Ab. Conversely, physicians should be aware of possible co-existing MG in patients with NMOSD presenting with fluctuating muscle weakness, fatigability or double vision, which would normally be attributed to myelitis or brain stem involvement. Besides AQP4-Ab testing, CSF findings may be of help in some cases. Interestingly, 33% of all patients reported so far were positive for CSF-restricted OCBs and more than 40% showed CSF pleocytosis, which is unusual in MG but is in line with previous reports on CSF pathology in NMOSD.<sup><xref ref-type="bibr" rid="bibr35-1352458511431728">35</xref>,<xref ref-type="bibr" rid="bibr36-1352458511431728">36</xref></sup></p>
<p>It is of note that MG took a rather mild course in most cases with clinical long-term remission, in the absence of immunosuppressive treatment in many of them. At last follow-up, MG symptoms were no longer present in 6/10 of our patients, and MG was well controlled with pyridostigmine in two. Similarly, in 9/12 patients reported in the previous literature, complete clinical remission of MG was reported and good control with pyridostigmine in one; one of the only two patients with active MG at the time of NMOSD had only mild symptoms (occasional ptosis and nasal voice).</p>
<p>By contrast, the clinical outcome from NMOSD was less favourable in the majority of cases. 62% of patients with available data had significant disability at last follow-up (including unilateral or bilateral blindness and/or para- or tetraplegia in some). A benign outcome at last follow-up was associated with short disease duration, with a low number of relapses, and with isolated LETM.</p>
<p>Including the authors’ own cases 21 cases of NMO and MG and five of LETM and MG have been reported to date. Based on the estimated prevalence of NMO (4.4:100.000 according to a recent Danish study; the prevalence of LETM is less well known)<sup><xref ref-type="bibr" rid="bibr37-1352458511431728">37</xref></sup> and that of MG (7.7:100.000),<sup><xref ref-type="bibr" rid="bibr38-1352458511431728">38</xref></sup> one would expect one case per 295 million subjects. Given the limited catchment areas of the 14 reporting centres it is therefore highly unlikely that the concurrent existence of the two conditions in the 21 patients with NMO and MG was by chance.</p>
<p>Among 168 German patients with NMOSD documented in the database of the German Neuromyelitis optica Study Group (NEMOS) (Jarius et al., submitted) patients 2, 3, 9, and 10 from the present series were the only patients with co-existing MG, corresponding to a frequency of 2.4%; if only patients with AQP4-Ab-positive NMOSD are considered (<italic>n</italic> = 132), the frequency was 3%.</p>
<p>Most population-based epidemiological studies show a higher incidence of MG in elderly patients.<sup><xref ref-type="bibr" rid="bibr38-1352458511431728">38</xref></sup> It is therefore of note that all patients with both NMOSD and MG reported thus far were &lt; 50 years at age of onset of MG, and around 20% had a juvenile onset. The median age of MG onset among patients with MG and NMOSD found in the present study (26 years) was identical to that usually observed in early-onset MG.<sup><xref ref-type="bibr" rid="bibr39-1352458511431728">39</xref><xref ref-type="bibr" rid="bibr40-1352458511431728"/>-<xref ref-type="bibr" rid="bibr41-1352458511431728">41</xref></sup></p>
<p>The sex ratio found in our study (male to female, 1:12) reflects the predominance of female cases in both NMO<sup><xref ref-type="bibr" rid="bibr42-1352458511431728">42</xref></sup> and MG.<sup><xref ref-type="bibr" rid="bibr43-1352458511431728">43</xref></sup> The proportion of females (92%) was slightly higher than that normally observed in patients with NMOSD (85% according to Wingerchuk et al.;<sup><xref ref-type="bibr" rid="bibr19-1352458511431728">19</xref></sup> 85% in our own series, <italic>n</italic> = 168; Jarius et al., submitted).</p>
<p>While most previous studies reported on patients from Japan or from countries with a high proportion of inhabitants of Asian or African descent, all of our own patients were seen at centres in continental European regions with mostly Caucasian inhabitants. This explains the difference in ethnicity between our own series and the previously published cases.</p>
<p>The exact contribution of thymectomy to the development of NMOSD is unclear. Given that thymectomy is a common therapy for MG and that NMOSD occurred with a latency of up to several years (median 12 years; range 0.3–32), this association could simply be coincidental. However, 73% of all patients reported so far had undergone thymectomy (including six of our cases) prior to onset of NMOSD. Moreover, hints that thymectomy might render patients susceptible to certain types of autoimmunity come from a number of retrospective and case studies reporting systemic lupus erythematosus,<sup><xref ref-type="bibr" rid="bibr44-1352458511431728">44</xref><xref ref-type="bibr" rid="bibr45-1352458511431728"/><xref ref-type="bibr" rid="bibr46-1352458511431728"/><xref ref-type="bibr" rid="bibr47-1352458511431728"/>-<xref ref-type="bibr" rid="bibr48-1352458511431728">48</xref></sup> microscopic polyangiitis,<sup><xref ref-type="bibr" rid="bibr49-1352458511431728">49</xref></sup> rheumatoid arthritis,<sup><xref ref-type="bibr" rid="bibr46-1352458511431728">46</xref></sup> alopecia areata,<sup><xref ref-type="bibr" rid="bibr50-1352458511431728">50</xref></sup> autoimmune haemolytic anaemia,<sup><xref ref-type="bibr" rid="bibr51-1352458511431728">51</xref></sup> or pancytopenia<sup><xref ref-type="bibr" rid="bibr52-1352458511431728">52</xref></sup> after thymectomy. In a long-term follow-up of MG patients who underwent thymectomy, Gerli et al. reported occurrence of additional autoimmune diseases in 12.5% of patients and at least one expansion within the CD8 and CD4 T-cell repertoire in 60% of patients.<sup><xref ref-type="bibr" rid="bibr48-1352458511431728">48</xref></sup> Furthermore, the frequency of various organ- and non-organ-specific autoantibodies including antinuclear, anti-double-stranded DNA, and anti-cardiolipin antibodies, was found to be significantly higher in MG patients after thymectomy than in those without thymectomy or healthy controls.<sup><xref ref-type="bibr" rid="bibr48-1352458511431728">48</xref></sup> Interestingly, 9/10 patients from our cohort had further, co-existing autoimmune disorders or were positive for additional autoantibodies (<xref ref-type="table" rid="table1-1352458511431728">Table 1</xref>). Further indications for a possible role of thymectomy in promoting autoimmunity come from a number of animal models.<sup><xref ref-type="bibr" rid="bibr53-1352458511431728">53</xref><xref ref-type="bibr" rid="bibr54-1352458511431728"/><xref ref-type="bibr" rid="bibr55-1352458511431728"/>-<xref ref-type="bibr" rid="bibr56-1352458511431728">56</xref></sup></p>
<p>Besides thymectomy itself, a role of immunosuppressants, especially of cyclophosphamide, in the induction of autoimmunity following thymectomy has been discussed.<sup><xref ref-type="bibr" rid="bibr57-1352458511431728">57</xref>,<xref ref-type="bibr" rid="bibr58-1352458511431728">58</xref></sup> However, only two of our patients had been treated with immunosuppressants at any time prior to onset of NMO (neither with cyclophosphamide), which largely rules out the possibility that such mechanisms played a major role in our cohort. Similarly, pretreatment with immunosuppressants has been reported in only three previously reported cases (2 × azathioprine, 1 × tacrolimus).</p>
<p>Finally, AQP4 expression in human thymoma tissue and, accordingly, binding of NMO-IgG-positive sera to thymoma cells has been recently described.<sup><xref ref-type="bibr" rid="bibr59-1352458511431728">59</xref></sup> However, NMO is not associated with tumours in most cases,<sup><xref ref-type="bibr" rid="bibr60-1352458511431728">60</xref></sup> and only a single case of thymoma associated with NMO has been reported to date.<sup><xref ref-type="bibr" rid="bibr20-1352458511431728">20</xref></sup></p>
<p>In summary, our study demonstrates that i) MG is more commonly associated with AQP4-Ab-positive NMOSD in Caucasians than expected; ii) MG precedes NMOSD in most cases, often by more than a decade; iii) NMOSD almost exclusively occurs in females with juvenile or early-onset MG; and iv) MG frequently takes a mild course in patients with NMOSD, usually not requiring immunosuppression. A history of thymectomy could be a possible risk factor for the later development of NMOSD. We recommend testing for AQP4-Ab and performing spinal cord and/or brain imaging in MG patients presenting with atypical motor or optic symptoms.</p>
</sec>
</body>
<back>
<ack>
<p>We would like to thank Anna Eschlbeck, Brigitte Fritz, and the Nikon Imaging Center, University of Heidelberg, for excellent technical assistance.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was supported by a Research Fellowship from the European Neurological Society (ENS) to SJ, a Research Fellowship from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) to SJ, by grants from Bayer Schering Pharma and from Merck Serono to BW, and by the German Research Foundation (DFG Exc 257 to FP).</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors have reported no competing interests.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511431728">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Hogancamp</surname><given-names>WF</given-names></name>
<name><surname>O’Brien</surname><given-names>PC</given-names></name>
<name><surname>Weinshenker</surname><given-names>BG</given-names></name>
</person-group>. <article-title>The clinical course of neuromyelitis optica (Devic’s syndrome)</article-title>. <source>Neurology</source> <year>1999</year>; <volume>53</volume>: <fpage>1107</fpage>–<lpage>1114</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511431728">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cree</surname><given-names>BA</given-names></name>
<name><surname>Goodin</surname><given-names>DS</given-names></name>
<name><surname>Hauser</surname><given-names>SL</given-names></name>
</person-group>. <article-title>Neuromyelitis optica</article-title>. <source>Semin Neurol</source> <year>2002</year>; <volume>22</volume>: <fpage>105</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511431728">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Paul</surname><given-names>F</given-names></name>
<name><surname>Franciotta</surname><given-names>D</given-names></name>
<name><surname>Waters</surname><given-names>P</given-names></name>
<name><surname>Zipp</surname><given-names>F</given-names></name>
<name><surname>Hohlfeld</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica</article-title>. <source>Nat Clin Pract Neurol</source> <year>2008</year>; <volume>4</volume>: <fpage>202</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511431728">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Wildemann</surname><given-names>B</given-names></name>
</person-group>. <article-title>AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance</article-title>. <source>Nat Rev Neurol</source> <year>2010</year>; <volume>6</volume>: <fpage>383</fpage>–<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511431728">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Seze</surname><given-names>J</given-names></name>
<name><surname>Stojkovic</surname><given-names>T</given-names></name>
<name><surname>Ferriby</surname><given-names>D</given-names></name>
<name><surname>Gauvrit</surname><given-names>JY</given-names></name>
<name><surname>Montagne</surname><given-names>C</given-names></name>
<name><surname>Mounier-Vehier</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile</article-title>. <source>J Neurol Sci</source> <year>2002</year>; <volume>197</volume>: <fpage>57</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511431728">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Franciotta</surname><given-names>D</given-names></name>
<name><surname>Bergamaschi</surname><given-names>R</given-names></name>
<name><surname>Wright</surname><given-names>H</given-names></name>
<name><surname>Littleton</surname><given-names>E</given-names></name>
<name><surname>Palace</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>NMO-IgG in the diagnosis of neuromyelitis optica</article-title>. <source>Neurology</source> <year>2007</year>; <volume>68</volume>: <fpage>1076</fpage>–<lpage>1077</lpage>.</citation>
</ref>
<ref id="bibr7-1352458511431728">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Kryzer</surname><given-names>TJ</given-names></name>
<name><surname>Pittock</surname><given-names>SJ</given-names></name>
<name><surname>Lucchinetti</surname><given-names>CF</given-names></name>
<name><surname>Fujihara</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis</article-title>. <source>Lancet</source> <year>2004</year>; <volume>364</volume>: <fpage>2106</fpage>–<lpage>2112</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511431728">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>Kryzer</surname><given-names>TJ</given-names></name>
<name><surname>Pittock</surname><given-names>SJ</given-names></name>
<name><surname>Verkman</surname><given-names>AS</given-names></name>
<name><surname>Hinson</surname><given-names>SR</given-names></name>
</person-group>. <article-title>IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel</article-title>. <source>J Exp Med</source> <year>2005</year>; <volume>202</volume>: <fpage>473</fpage>–<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511431728">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paul</surname><given-names>F</given-names></name>
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Aktas</surname><given-names>O</given-names></name>
<name><surname>Bluthner</surname><given-names>M</given-names></name>
<name><surname>Bauer</surname><given-names>O</given-names></name>
<name><surname>Appelhans</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica</article-title>. <source>PLoS Med</source> <year>2007</year>; <volume>4</volume>: <fpage>e133</fpage>.</citation>
</ref>
<ref id="bibr10-1352458511431728">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bradl</surname><given-names>M</given-names></name>
<name><surname>Misu</surname><given-names>T</given-names></name>
<name><surname>Takahashi</surname><given-names>T</given-names></name>
<name><surname>Watanabe</surname><given-names>M</given-names></name>
<name><surname>Mader</surname><given-names>S</given-names></name>
<name><surname>Reindl</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo</article-title>. <source>Ann Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>630</fpage>–<lpage>643</lpage>.</citation>
</ref>
<ref id="bibr11-1352458511431728">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>JL</given-names></name>
<name><surname>Lam</surname><given-names>C</given-names></name>
<name><surname>Kalluri</surname><given-names>SR</given-names></name>
<name><surname>Saikali</surname><given-names>P</given-names></name>
<name><surname>Bautista</surname><given-names>K</given-names></name>
<name><surname>Dupree</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica</article-title>. <source>Ann Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>617</fpage>–<lpage>629</lpage>.</citation>
</ref>
<ref id="bibr12-1352458511431728">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saadoun</surname><given-names>S</given-names></name>
<name><surname>Waters</surname><given-names>P</given-names></name>
<name><surname>Bell</surname><given-names>BA</given-names></name>
<name><surname>Vincent</surname><given-names>A</given-names></name>
<name><surname>Verkman</surname><given-names>AS</given-names></name>
<name><surname>Papadopoulos</surname><given-names>MC</given-names></name>
</person-group>. <article-title>Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice</article-title>. <source>Brain</source> <year>2010</year>; <volume>133</volume>: <fpage>349</fpage>–<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr13-1352458511431728">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Aboul-Enein</surname><given-names>F</given-names></name>
<name><surname>Waters</surname><given-names>P</given-names></name>
<name><surname>Kuenz</surname><given-names>B</given-names></name>
<name><surname>Hauser</surname><given-names>A</given-names></name>
<name><surname>Berger</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Antibody to aquaporin-4 in the long-term course of neuromyelitis optica</article-title>. <source>Brain</source> <year>2008</year>; <volume>131</volume>: <fpage>3072</fpage>–<lpage>3080</lpage>.</citation>
</ref>
<ref id="bibr14-1352458511431728">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wandinger</surname><given-names>KP</given-names></name>
<name><surname>Stangel</surname><given-names>M</given-names></name>
<name><surname>Witte</surname><given-names>T</given-names></name>
<name><surname>Venables</surname><given-names>P</given-names></name>
<name><surname>Charles</surname><given-names>P</given-names></name>
<name><surname>Jarius</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren’s syndrome</article-title>. <source>Arthritis Rheum</source> <year>2010</year>; <volume>62</volume>: <fpage>1198</fpage>–<lpage>1200</lpage>.</citation>
</ref>
<ref id="bibr15-1352458511431728">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pittock</surname><given-names>SJ</given-names></name>
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>de Seze</surname><given-names>J</given-names></name>
<name><surname>Vermersch</surname><given-names>P</given-names></name>
<name><surname>Homburger</surname><given-names>HA</given-names></name>
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<etal/>
</person-group>. <article-title>Neuromyelitis optica and non organ-specific autoimmunity</article-title>. <source>Arch Neurol</source> <year>2008</year>; <volume>65</volume>: <fpage>78</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr16-1352458511431728">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Jacobi</surname><given-names>C</given-names></name>
<name><surname>de Seze</surname><given-names>J</given-names></name>
<name><surname>Zephir</surname><given-names>H</given-names></name>
<name><surname>Paul</surname><given-names>F</given-names></name>
<name><surname>Franciotta</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>1067</fpage>–<lpage>1073</lpage>.</citation>
</ref>
<ref id="bibr17-1352458511431728">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinshenker</surname><given-names>BG</given-names></name>
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Vukusic</surname><given-names>S</given-names></name>
<name><surname>Linbo</surname><given-names>L</given-names></name>
<name><surname>Pittock</surname><given-names>SJ</given-names></name>
<name><surname>Lucchinetti</surname><given-names>CF</given-names></name>
<etal/>
</person-group>. <article-title>Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis</article-title>. <source>Ann Neurol</source> <year>2006</year>; <volume>59</volume>: <fpage>566</fpage>–<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr18-1352458511431728">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Frederikson</surname><given-names>J</given-names></name>
<name><surname>Waters</surname><given-names>P</given-names></name>
<name><surname>Paul</surname><given-names>F</given-names></name>
<name><surname>Akman-Demir</surname><given-names>G</given-names></name>
<name><surname>Marignier</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis</article-title>. <source>J Neurol Sci</source> <year>2010</year>; <volume>298</volume>: <fpage>158</fpage>–<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr19-1352458511431728">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>Pittock</surname><given-names>SJ</given-names></name>
<name><surname>Lucchinetti</surname><given-names>CF</given-names></name>
<name><surname>Weinshenker</surname><given-names>BG</given-names></name>
</person-group>. <article-title>Revised diagnostic criteria for neuromyelitis optica</article-title>. <source>Neurology</source> <year>2006</year>; <volume>66</volume>: <fpage>1485</fpage>–<lpage>1489</lpage>.</citation>
</ref>
<ref id="bibr20-1352458511431728">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Antoine</surname><given-names>JC</given-names></name>
<name><surname>Camdessanche</surname><given-names>JP</given-names></name>
<name><surname>Absi</surname><given-names>L</given-names></name>
<name><surname>Lassabliere</surname><given-names>F</given-names></name>
<name><surname>Feasson</surname><given-names>L</given-names></name>
</person-group>. <article-title>Devic disease and thymoma with anti-central nervous system and antithymus antibodies</article-title>. <source>Neurology</source> <year>2004</year>; <volume>62</volume>: <fpage>978</fpage>–<lpage>980</lpage>.</citation>
</ref>
<ref id="bibr21-1352458511431728">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bichuetti</surname><given-names>DB</given-names></name>
<name><surname>Barros</surname><given-names>TM</given-names></name>
<name><surname>Oliveira</surname><given-names>EM</given-names></name>
<name><surname>Annes</surname><given-names>M</given-names></name>
<name><surname>Gabbai</surname><given-names>AA</given-names></name>
</person-group>. <article-title>Demyelinating disease in patients with myasthenia gravis</article-title>. <source>Arq Neuropsiquiatr</source> <year>2008</year>; <volume>66</volume>: <fpage>5</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr22-1352458511431728">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furukawa</surname><given-names>Y</given-names></name>
<name><surname>Yoshikawa</surname><given-names>H</given-names></name>
<name><surname>Yachie</surname><given-names>A</given-names></name>
<name><surname>Yamada</surname><given-names>M</given-names></name>
</person-group>. <article-title>Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population</article-title>. <source>Eur J Neurol</source> <year>2006</year>; <volume>13</volume>: <fpage>655</fpage>–<lpage>658</lpage>.</citation>
</ref>
<ref id="bibr23-1352458511431728">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ikeda</surname><given-names>K</given-names></name>
<name><surname>Araki</surname><given-names>Y</given-names></name>
<name><surname>Iwasaki</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Occurrence of CNS demyelinating disease in patients with myasthenia gravis</article-title>. <source>Neurology</source> <year>2007</year>; <volume>68</volume>: <fpage>1326</fpage>; <comment>author reply 27</comment>.</citation>
</ref>
<ref id="bibr24-1352458511431728">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isbister</surname><given-names>CM</given-names></name>
<name><surname>Mackenzie</surname><given-names>PJ</given-names></name>
<name><surname>Anderson</surname><given-names>D</given-names></name>
<name><surname>Wade</surname><given-names>NK</given-names></name>
<name><surname>Oger</surname><given-names>J</given-names></name>
</person-group>. <article-title>Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia</article-title>. <source>Mult Scler</source> <year>2003</year>; <volume>9</volume>: <fpage>550</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr25-1352458511431728">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>M</given-names></name>
<name><surname>Nakashima</surname><given-names>I</given-names></name>
<name><surname>Sato</surname><given-names>S</given-names></name>
<name><surname>Miyazawa</surname><given-names>I</given-names></name>
<name><surname>Fujihara</surname><given-names>K</given-names></name>
<name><surname>Itoyama</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Clinical and laboratory features of neuromyelitis optica with oligoclonal IgG bands</article-title>. <source>Mult Scler</source> <year>2007</year>; <volume>13</volume>: <fpage>332</fpage>–<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr26-1352458511431728">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kay</surname><given-names>CS</given-names></name>
<name><surname>Scola</surname><given-names>RH</given-names></name>
<name><surname>Lorenzoni</surname><given-names>PJ</given-names></name>
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Arruda</surname><given-names>WO</given-names></name>
<name><surname>Werneck</surname><given-names>LC</given-names></name>
</person-group>. <article-title>NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy</article-title>. <source>J Neurol Sci</source> <year>2008</year>; <volume>275</volume>: <fpage>148</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr27-1352458511431728">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uzawa</surname><given-names>A</given-names></name>
<name><surname>Mori</surname><given-names>M</given-names></name>
<name><surname>Iwai</surname><given-names>Y</given-names></name>
<name><surname>Kobayashi</surname><given-names>M</given-names></name>
<name><surname>Hayakawa</surname><given-names>S</given-names></name>
<name><surname>Kawaguchi</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis</article-title>. <source>J Neurol Sci</source> <year>2009</year> <volume>287</volume>: <fpage>105</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr28-1352458511431728">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kister</surname><given-names>I</given-names></name>
<name><surname>Gulati</surname><given-names>S</given-names></name>
<name><surname>Boz</surname><given-names>C</given-names></name>
<name><surname>Bergamaschi</surname><given-names>R</given-names></name>
<name><surname>Piccolo</surname><given-names>G</given-names></name>
<name><surname>Oger</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy</article-title>. <source>Arch Neurol</source> <year>2006</year>; <volume>63</volume>: <fpage>851</fpage>–<lpage>856</lpage>.</citation>
</ref>
<ref id="bibr29-1352458511431728">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gotkine</surname><given-names>M</given-names></name>
<name><surname>Fellig</surname><given-names>Y</given-names></name>
<name><surname>Abramsky</surname><given-names>O</given-names></name>
</person-group>. <article-title>Occurrence of CNS demyelinating disease in patients with myasthenia gravis</article-title>. <source>Neurology</source> <year>2006</year>; <volume>67</volume>: <fpage>881</fpage>-<lpage>883.30</lpage>.</citation>
</ref>
<ref id="bibr30-1352458511431728">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Riordan</surname><given-names>JI</given-names></name>
<name><surname>Gallagher</surname><given-names>HL</given-names></name>
<name><surname>Thompson</surname><given-names>AJ</given-names></name>
<name><surname>Howard</surname><given-names>RS</given-names></name>
<name><surname>Kingsley</surname><given-names>DP</given-names></name>
<name><surname>Thompson</surname><given-names>EJ</given-names></name>
<etal/>
</person-group>. <article-title>Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>1996</year>; <volume>60</volume>: <fpage>382</fpage>–<lpage>387</lpage>.</citation>
</ref>
<ref id="bibr31-1352458511431728">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waters</surname><given-names>P</given-names></name>
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Littleton</surname><given-names>E</given-names></name>
<name><surname>Leite</surname><given-names>MI</given-names></name>
<name><surname>Jacob</surname><given-names>S</given-names></name>
<name><surname>Gray</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis</article-title>. <source>Arch Neurol</source> <year>2008</year>; <volume>65</volume>: <fpage>913</fpage>–<lpage>919</lpage>.</citation>
</ref>
<ref id="bibr32-1352458511431728">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chan</surname><given-names>KH</given-names></name>
<name><surname>Kwan</surname><given-names>JS</given-names></name>
<name><surname>Ho</surname><given-names>PW</given-names></name>
<name><surname>Ho</surname><given-names>JW</given-names></name>
<name><surname>Chu</surname><given-names>AC</given-names></name>
<name><surname>Ramsden</surname><given-names>DB</given-names></name>
</person-group>. <article-title>Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays</article-title>. <source>J Neuroinflamm</source> <year>2010</year>; <volume>7</volume>: <fpage>50</fpage>.</citation>
</ref>
<ref id="bibr33-1352458511431728">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takahashi</surname><given-names>T</given-names></name>
<name><surname>Fujihara</surname><given-names>K</given-names></name>
<name><surname>Nakashima</surname><given-names>I</given-names></name>
<name><surname>Misu</surname><given-names>T</given-names></name>
<name><surname>Miyazawa</surname><given-names>I</given-names></name>
<name><surname>Nakamura</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre</article-title>. <source>Brain</source> <year>2007</year>; <volume>130</volume>: <fpage>1235</fpage>–<lpage>1243</lpage>.</citation>
</ref>
<ref id="bibr34-1352458511431728">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Probst</surname><given-names>C</given-names></name>
<name><surname>Borowski</surname><given-names>K</given-names></name>
<name><surname>Franciotta</surname><given-names>D</given-names></name>
<name><surname>Wildemann</surname><given-names>B</given-names></name>
<name><surname>Stoecker</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen</article-title>. <source>J Neurol Sci</source> <year>2010</year>; <volume>291</volume>: <fpage>52</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr35-1352458511431728">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Franciotta</surname><given-names>D</given-names></name>
<name><surname>Paul</surname><given-names>F</given-names></name>
<name><surname>Ruprecht</surname><given-names>K</given-names></name>
<name><surname>Bergamaschi</surname><given-names>R</given-names></name>
<name><surname>Rommer</surname><given-names>PS</given-names></name>
<etal/>
</person-group>. <article-title>Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance</article-title>. <source>J Neuroinflamm</source> <year>2010</year>; <volume>7</volume>: <fpage>52</fpage>.</citation>
</ref>
<ref id="bibr36-1352458511431728">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarius</surname><given-names>S</given-names></name>
<name><surname>Paul</surname><given-names>F</given-names></name>
<name><surname>Franciotta</surname><given-names>D</given-names></name>
<name><surname>Ruprecht</surname><given-names>K</given-names></name>
<name><surname>Ringelstein</surname><given-names>M</given-names></name>
<name><surname>Bergamaschi</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures</article-title>. <source>J Neurol Sci</source> <year>2011</year>; <volume>306</volume>: <fpage>82</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr37-1352458511431728">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Asgari</surname><given-names>N</given-names></name>
<name><surname>Lillevang</surname><given-names>ST</given-names></name>
<name><surname>Skejoe</surname><given-names>HP</given-names></name>
<name><surname>Falah</surname><given-names>M</given-names></name>
<name><surname>Stenager</surname><given-names>E</given-names></name>
<name><surname>Kyvik</surname><given-names>KO</given-names></name>
</person-group>. <article-title>A population-based study of neuromyelitis optica in Caucasians</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>1589</fpage>–<lpage>1595</lpage>.</citation>
</ref>
<ref id="bibr38-1352458511431728">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carr</surname><given-names>AS</given-names></name>
<name><surname>Cardwell</surname><given-names>CR</given-names></name>
<name><surname>McCarron</surname><given-names>PO</given-names></name>
<name><surname>McConville</surname><given-names>J</given-names></name>
</person-group>. <article-title>A systematic review of population based epidemiological studies in myasthenia gravis</article-title>. <source>BMC Neurol</source> <year>2010</year>; <volume>10</volume>: <fpage>46</fpage>.</citation>
</ref>
<ref id="bibr39-1352458511431728">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mantegazza</surname><given-names>R</given-names></name>
<name><surname>Baggi</surname><given-names>F</given-names></name>
<name><surname>Antozzi</surname><given-names>C</given-names></name>
<name><surname>Confalonieri</surname><given-names>P</given-names></name>
<name><surname>Morandi</surname><given-names>L</given-names></name>
<name><surname>Bernasconi</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Myasthenia gravis (MG): epidemiological data and prognostic factors</article-title>. <source>Ann N Y Acad Sci</source> <year>2003</year>; <volume>998</volume>: <fpage>413</fpage>–<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr40-1352458511431728">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aarli</surname><given-names>JA</given-names></name>
<name><surname>Romi</surname><given-names>F</given-names></name>
<name><surname>Skeie</surname><given-names>GO</given-names></name>
<name><surname>Gilhus</surname><given-names>NE</given-names></name>
</person-group>. <article-title>Myasthenia gravis in individuals over 40</article-title>. <source>Ann N Y Acad Sci</source> <year>2003</year>; <volume>998</volume>: <fpage>424</fpage>–<lpage>431</lpage>.</citation>
</ref>
<ref id="bibr41-1352458511431728">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>PB</given-names></name>
<name><surname>Jensen</surname><given-names>TS</given-names></name>
<name><surname>Tsiropoulos</surname><given-names>I</given-names></name>
<name><surname>Sorensen</surname><given-names>T</given-names></name>
<name><surname>Kjaer</surname><given-names>M</given-names></name>
<name><surname>Hojer-Pedersen</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989</article-title>. <source>Neurology</source> <year>1993</year>; <volume>43</volume>: <fpage>1779</fpage>–<lpage>1783</lpage>.</citation>
</ref>
<ref id="bibr42-1352458511431728">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Neuromyelitis optica: Effect of gender</article-title>. <source>J Neurol Sci</source> <year>2009</year>; <volume>286</volume>: <fpage>18</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr43-1352458511431728">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McGrogan</surname><given-names>A</given-names></name>
<name><surname>Sneddon</surname><given-names>S</given-names></name>
<name><surname>de Vries</surname><given-names>CS</given-names></name>
</person-group>. <article-title>The incidence of myasthenia gravis: a systematic literature review</article-title>. <source>Neuroepidemiology</source> <year>2010</year>; <volume>34</volume>: <fpage>171</fpage>–<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr44-1352458511431728">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mevorach</surname><given-names>D</given-names></name>
<name><surname>Perrot</surname><given-names>S</given-names></name>
<name><surname>Buchanan</surname><given-names>N</given-names></name>
<name><surname>Khamashta</surname><given-names>M</given-names></name>
<name><surname>Laoussadi</surname><given-names>S</given-names></name>
<name><surname>Hughes</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Appearance of systemic lupus erythematosus after thymectomy: four case reports and review of the literature</article-title>. <source>Lupus</source> <year>1995</year>; <volume>4</volume>: <fpage>33</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr45-1352458511431728">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sant</surname><given-names>S</given-names></name>
</person-group>. <article-title>Systemic lupus erythematosus after thymectomy in a patient with myasthenia gravis</article-title>. <source>Ir Med J</source> <year>1997</year>; <volume>90</volume>: <fpage>116</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr46-1352458511431728">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zonana</surname><given-names>M</given-names></name>
<name><surname>Reyes</surname><given-names>E</given-names></name>
<name><surname>Weisman</surname><given-names>A</given-names></name>
</person-group>. <article-title>Coexistence of four autoimmune diseases in one patient: the kaleidoscope of autoimmunity</article-title>. <source>J Clin Rheumatol</source> <year>2002</year>; <volume>8</volume>: <fpage>322</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr47-1352458511431728">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosman</surname><given-names>A</given-names></name>
<name><surname>Atsumi</surname><given-names>T</given-names></name>
<name><surname>Khamashta</surname><given-names>M</given-names></name>
<name><surname>Ames</surname><given-names>P</given-names></name>
<name><surname>Hughes</surname><given-names>G</given-names></name>
</person-group>. <article-title>Development of systemic lupus erythematosus after chemotherapy and radiotherapy for malignant thymoma</article-title>. <source>Br J Rheumatol</source> <year>1995</year>; <volume>34</volume>: <fpage>1175</fpage>–<lpage>1176</lpage>.</citation>
</ref>
<ref id="bibr48-1352458511431728">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerli</surname><given-names>R</given-names></name>
<name><surname>Paganelli</surname><given-names>R</given-names></name>
<name><surname>Cossarizza</surname><given-names>A</given-names></name>
<name><surname>Muscat</surname><given-names>C</given-names></name>
<name><surname>Piccolo</surname><given-names>G</given-names></name>
<name><surname>Barbieri</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Long-term immunologic effects of thymectomy in patients with myasthenia gravis</article-title>. <source>J Allergy Clin Immunol</source> <year>1999</year>; <volume>103</volume>: <fpage>865</fpage>–<lpage>872</lpage>.</citation>
</ref>
<ref id="bibr49-1352458511431728">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parambil</surname><given-names>J</given-names></name>
<name><surname>Keogh</surname><given-names>K</given-names></name>
<name><surname>Fervenza</surname><given-names>F</given-names></name>
<name><surname>Ryu</surname><given-names>J</given-names></name>
</person-group>. <article-title>Microscopic polyangiitis associated with thymoma, exacerbating after thymectomy</article-title>. <source>Am J Kidney Dis</source> <year>2006</year>; <volume>48</volume>: <fpage>827</fpage>–<lpage>831</lpage>.</citation>
</ref>
<ref id="bibr50-1352458511431728">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>S</given-names></name>
<name><surname>Shimoda</surname><given-names>M</given-names></name>
<name><surname>Kawamura</surname><given-names>M</given-names></name>
<name><surname>Sato</surname><given-names>H</given-names></name>
<name><surname>Nogawa</surname><given-names>S</given-names></name>
<name><surname>Tanaka</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Myasthenia gravis accompanied by alopecia areata: clinical and immunogenetic aspects</article-title>. <source>Eur J Neurol</source> <year>2005</year>; <volume>12</volume>: <fpage>566</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr51-1352458511431728">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wakata</surname><given-names>N</given-names></name>
<name><surname>Kiyozuka</surname><given-names>T</given-names></name>
<name><surname>Konno</surname><given-names>S</given-names></name>
<name><surname>Nakazora</surname><given-names>H</given-names></name>
<name><surname>Nomoto</surname><given-names>N</given-names></name>
<name><surname>Sugimoto</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Autoimmune thrombocytopenic purpura, autoimmune hemolytic anemia and gastric cancer appeared in a patient with myasthenia gravis</article-title>. <source>Intern Med</source> <year>2006</year>; <volume>45</volume>: <fpage>479</fpage>–<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr52-1352458511431728">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gonlugur</surname><given-names>U</given-names></name>
<name><surname>Sahin</surname><given-names>E</given-names></name>
<name><surname>Yildiz</surname><given-names>E</given-names></name>
<name><surname>Gonlugur</surname><given-names>TE</given-names></name>
</person-group>. <article-title>Early autoimmune complications after thymomectomy in a patient with interstitial lung disease. Case report</article-title>. <source>Acta Microbiol Immunol Hung</source> <year>2006</year>; <volume>53</volume>: <fpage>105</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr53-1352458511431728">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kojima</surname><given-names>A</given-names></name>
<name><surname>Prehn</surname><given-names>R</given-names></name>
</person-group>. <article-title>Genetic susceptibility to post-thymectomy autoimmune diseases in mice</article-title>. <source>Immunogenetics</source> <year>1981</year>; <volume>14</volume>: <fpage>15</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr54-1352458511431728">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Itoh</surname><given-names>M</given-names></name>
<name><surname>Takahashi</surname><given-names>T</given-names></name>
<name><surname>Sakaguchi</surname><given-names>N</given-names></name>
<name><surname>Kuniyasu</surname><given-names>Y</given-names></name>
<name><surname>Shimizu</surname><given-names>J</given-names></name>
<name><surname>Otsuka</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance</article-title>. <source>J Immunol</source> <year>1999</year>; <volume>162</volume>: <fpage>5317</fpage>–<lpage>5326</lpage>.</citation>
</ref>
<ref id="bibr55-1352458511431728">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Asano</surname><given-names>M</given-names></name>
<name><surname>Toda</surname><given-names>M</given-names></name>
<name><surname>Sakaguchi</surname><given-names>N</given-names></name>
<name><surname>Sakaguchi</surname><given-names>S</given-names></name>
</person-group>. <article-title>Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation</article-title>. <source>J Exp Med</source> <year>1996</year>; <volume>184</volume>: <fpage>387</fpage>–<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr56-1352458511431728">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chi</surname><given-names>Y</given-names></name>
<name><surname>Fan</surname><given-names>Y</given-names></name>
<name><surname>He</surname><given-names>L</given-names></name>
<name><surname>Liu</surname><given-names>W</given-names></name>
<name><surname>Wen</surname><given-names>X</given-names></name>
<name><surname>Zhou</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Novel role of aquaporin-4 in CD4(+) CD25(+) T regulatory cell development and severity of Parkinson’s disease</article-title>. <source>Aging Cell</source> <year>2011</year>; <volume>10</volume>: <fpage>368</fpage>–<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr57-1352458511431728">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barrett</surname><given-names>S</given-names></name>
<name><surname>Toh</surname><given-names>B</given-names></name>
<name><surname>Alderuccio</surname><given-names>F</given-names></name>
<name><surname>van Driel</surname><given-names>I</given-names></name>
<name><surname>Gleeson</surname><given-names>P</given-names></name>
</person-group>. <article-title>Organ-specific autoimmunity induced by adult thymectomy and cyclophosphamide-induced lymphopenia</article-title>. <source>Eur J Immunol</source> <year>1995</year>; <volume>25</volume>: <fpage>238</fpage>–<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr58-1352458511431728">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schulze-Koops</surname><given-names>H</given-names></name>
</person-group>. <article-title>Lymphopenia and autoimmune diseases</article-title>. <source>Arthritis Res Ther</source> <year>2004</year>; <volume>6</volume>: <fpage>178</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr59-1352458511431728">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chan</surname><given-names>KH</given-names></name>
<name><surname>Kwan</surname><given-names>JS</given-names></name>
<name><surname>Ho</surname><given-names>PW</given-names></name>
<name><surname>Ho</surname><given-names>SL</given-names></name>
<name><surname>Chui</surname><given-names>WH</given-names></name>
<name><surname>Chu</surname><given-names>AC</given-names></name>
<etal/>
</person-group>. <article-title>Aquaporin-4 water channel expression by thymoma of patients with and without myasthenia gravis</article-title>. <source>J Neuroimmunol</source> <year>2010</year>; <volume>227</volume>: <fpage>178</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr60-1352458511431728">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pittock</surname><given-names>SJ</given-names></name>
<name><surname>Lennon</surname><given-names>VA</given-names></name>
</person-group>. <article-title>Aquaporin-4 autoantibodies in a paraneoplastic context</article-title>. <source>Arch Neurol</source> <year>2008</year>; <volume>65</volume>: <fpage>629</fpage>–<lpage>632</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>